Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma

被引:43
|
作者
He, Chaobin [1 ]
Zhang, Yu [2 ]
Song, Yunda [1 ]
Wang, Jun [1 ]
Xing, Kaili [1 ]
Lin, Xiaojun [1 ]
Li, Shengping [1 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Hepatobiliary & Pancreat Surg,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China
来源
JOURNAL OF CANCER | 2018年 / 9卷 / 17期
基金
中国国家自然科学基金;
关键词
Intrahepatic cholangiocarcinoma; Surgical outcome; Biomarker; Prognosis; CARBOHYDRATE ANTIGEN 19-9; SURGICAL-TREATMENT; TUMOR-MARKERS; PRIMARY LIVER; MANAGEMENT; RECURRENCE; DIAGNOSIS; OUTCOMES; BIOMARKERS; SURVIVAL;
D O I
10.7150/jca.25339
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: There are few diagnostic tools that can be used to determine which patient with intrahepatic cholangiocarcinoma (ICC) can benefit from surgery actually, highlighting that the need for new preoperative stratification strategies. The aim of this study was to investigate the predictive values of preoperative biomarkers in survival analyses for patients with ICC after surgical resection. Methods: A total of 285 patients with ICC were retrospectively reviewed. Receiver operating charateristics (ROC) curves were used to evaluate the predictive effects of preoperative carbohydrate antigen 19-9 (CA19-9) with different cutoff values and carcinoembryonic antigen (CEA) in patients with ICC. Results: Preoperative CA19-9 with a cutoff value of 200 U/ml performed better in predicting overall survival (OS) and progression free survival (PFS) in ICC patients. Patients with preoperative CA19-9 value > 200 U/ml generally had a poor surgical response. However, surgical resection could also benefit patients whose CA19-9 levels decreased postoperatively or preoperative CEA levels were negative. Conclusions: With the cutoff value of 200U/ml, CA19-9 was a better preoperative biomarker for predicting survival for ICC patients after surgical resection. Combination of preoperative CA19-9 and CEA showed the strongest predictive power in survival analyses in these patients and should be recognized in daily clinical care.
引用
收藏
页码:3117 / 3128
页数:12
相关论文
共 50 条
  • [1] The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma
    Amika Moro
    Rittal Mehta
    Kota Sahara
    Diamantis I. Tsilimigras
    Anghela Z. Paredes
    Ayesha Farooq
    J. Madison Hyer
    Itaru Endo
    Feng Shen
    Alfredo Guglielmi
    Luca Aldrighetti
    Matthew Weiss
    Todd W. Bauer
    Sorin Alexandrescu
    George A. Poultsides
    Shishir K. Maithel
    Hugo P. Marques
    Guillaume Martel
    Carlo Pulitano
    Olivier Soubrane
    Bas G. Koerkamp
    Kazunari Sasaki
    Timothy M. Pawlik
    [J]. Annals of Surgical Oncology, 2020, 27 : 2888 - 2901
  • [2] The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma
    Moro, Amika
    Mehta, Rittal
    Sahara, Kota
    Tsilimigras, Diamantis, I
    Paredes, Anghela Z.
    Farooq, Ayesha
    Hyer, J. Madison
    Endo, Itaru
    Shen, Feng
    Guglielmi, Alfredo
    Aldrighetti, Luca
    Weiss, Matthew
    Bauer, Todd W.
    Alexandrescu, Sorin
    Poultsides, George A.
    Maithel, Shishir K.
    Marques, Hugo P.
    Martel, Guillaume
    Pulitano, Carlo
    Soubrane, Olivier
    Koerkamp, Bas G.
    Sasaki, Kazunari
    Pawlik, Timothy M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (08) : 2888 - 2901
  • [3] Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma
    Fang, Tianyi
    Wang, Hao
    Wang, Yufu
    Lin, Xuan
    Cui, Yunfu
    Wang, Zhidong
    [J]. DISEASE MARKERS, 2019, 2019
  • [4] Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?
    Wang, Jun-Ke
    Hu, Hai-Jie
    Shrestha, Anuj
    Ma, Wen-Jie
    Yang, Qin
    Liu, Fei
    Cheng, Nan-Sheng
    Li, Fu-Yu
    [J]. ONCOTARGET, 2017, 8 (28) : 45335 - 45344
  • [5] The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer
    Kodera, Y
    Yamamura, Y
    Torii, A
    Uesaka, K
    Hirai, T
    Yasui, K
    Morimoto, T
    Kato, T
    Kito, T
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 1996, 91 (01): : 49 - 53
  • [6] Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
    Kim, Young Choon
    Kim, Hong Joo
    Park, Jung Ho
    Park, Dong Il
    Cho, Yong Kyun
    Sohn, Chong Il
    Jeon, Woo Kyu
    Kim, Byung Ik
    Shin, Jun Ho
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (12) : 1869 - 1875
  • [7] Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma
    Xu, Hua-Xiang
    Liu, Liang
    Xiang, Jin-Feng
    Wang, Wen-Quan
    Qi, Zi-Hao
    Wu, Chun-Tao
    Liu, Chen
    Long, Jiang
    Xu, Jin
    Ni, Quan-Xing
    Yu, Xian-Jun
    [J]. SURGERY, 2017, 161 (02) : 373 - 384
  • [8] Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma
    Cai, Wen-Ke
    Lin, Jia-Ji
    He, Gong-Hao
    Wang, Hua
    Lu, Jun-Hua
    Yang, Guang-Shun
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (11): : 7890 - 7898
  • [9] Elevation of CA19-9 and CEA is associated with a poor prognosis in patients with resectable gallbladder carcinoma
    Wen, Zhijian
    Si, Anfeng
    Yang, Jue
    Yang, Pinghua
    Yang, Xinwei
    Liu, Hu
    Yan, Xingzhou
    Li, Wengang
    Zhang, Baohua
    [J]. HPB, 2017, 19 (11) : 951 - 956
  • [10] Accuracy of preoperative serum CA19-9 levels in predicting the resectability of patients with pancreatic adenocarcinoma
    Ying Li
    Xiaojuan Yang
    Zhanzhan Zhang
    Xiaoning Kang
    Shanglong Liu
    [J]. Oncology and Translational Medicine, 2018, 4 (01) : 6 - 9